[1]
2024. Which factors help to determine the long-term response to first-line tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma: A Turkish multi-centre study. Biomolecules and Biomedicine. 24, 6 (Oct. 2024), 1776–1784. DOI:https://doi.org/10.17305/bb.2024.10512.